Results 181 to 190 of about 20,950 (257)

Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study. [PDF]

Rheumatology (Oxford)
Zhao MH, Cons Molina F, Aroca G, Tektonidou MG, Mathur A, Tangadpalli R, Sun R, Martin R, Pellet P, Ngoc Phuong Huynh T.   +9 more
europepmc   +1 more source

Exploring clusters based on ultrasound-detected inflammation in patients with psoriatic arthritis: a post-hoc analysis from the ULTIMATE trial. [PDF]

BMC Musculoskelet Disord
D'Agostino MA, Conaghan PG, Gaillez C, Boers M, Naredo E, Mandl P, Carron P, López-Rdz A, Burgos-Vargas R, Rosa J, Bakewell C, Cazenave T, Bao W, Demanse D, Schett G.   +14 more
europepmc   +1 more source

Secukinumab compared to ixekizumab in biologic-naïve Chinese individuals afflicted with moderate-to-severe plaque psoriasis: A retrospective single-center analysis. [PDF]

Medicine (Baltimore)
Zhao D.
europepmc   +1 more source

Efficacy of secukinumab in pediatric patients with moderate to severe plaque psoriasis: A randomized study. [PDF]

Medicine (Baltimore)
Zhang Y, Lu X, Zhou Y, Lei L, Wang L, Liang N, Li C.   +6 more
europepmc   +1 more source

Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report. [PDF]

Front Med (Lausanne)
Wang L, Li Y, Li C, Zhang L, Zeng L.
europepmc   +1 more source

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex. [PDF]

Arthritis Res Ther
Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Kalogiannaki E, Kalligianni-Sofikiti K, Emmanouilidou E, Marolachaki E, Bertsias G, Sidiropoulos P.   +9 more
europepmc   +1 more source

Temporarily induced facial eczema by IL-17 inhibitors: a case report and literature review. [PDF]

Front Allergy
Zhang T, Meng F, He J, Li C, Zhao Z.
europepmc   +1 more source

Case Report: Acute generalized exanthematous pustulosis with psoriasis successfully treated with Secukinumab. [PDF]

Front Immunol
Zheng JN, Liu X, Shi Y, Gu J, Gong Y.
europepmc   +1 more source

Unexpected Hepatotoxicity in Psoriasis: Deranged Liver Enzymes and Steatosis Secondary to Secukinumab Treatment. [PDF]

ACG Case Rep J
Kumar G, Shah Y, Dahiya DS.
europepmc   +1 more source

Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against IL-Inhibitors for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons. [PDF]

Rheumatol Ther
Mestre-Ferrandiz J, Navarro-Compán V, Ivanova-Markova Y, González-Domínguez A, Maratia S.   +4 more
europepmc   +1 more source